1. Canada Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
NanoSphere Health Sciences Inc.

NanoSphere Health Sciences Inc.

NSHS.CN
NanoSphere Health Sciences Inc.CA flagCanadian Securities Exchange
0.02
CAD
- -
- -
205,504.00Market Cap
NanoSphere Health Sciences Inc.
NSHS.CN
(Canadian Securities Exchange)

Recent

price

0.02

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.01
0.04
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-84
-241.44
-79.17
-86.93
-1.03
-0.25
-0.43
-18.02
-0.93
-0.65
-0.11
-0.05
-0.03
-0.02
0.03
-0.01
-0.01
Basic EPS, GAAP
-2,023.83
-174.12
-84.34
-22.33
-1.77
-0.1
-0.25
-2.29
-0.67
-0.21
-0.01
-0.01
-0.01
-0.01
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-3,050.55
-254.01
-286.58
-256.99
-82.81
-27.97
-1.84
5.58
-0.02
-0.39
-0.49
-0.33
-0.25
-0.27
-0.25
-0.25
-0.25
Book Value per Share
2,099.76
156.19
135.29
-5.07
-0.63
-0.17
-0.28
6.69
0.17
-0.17
-0.27
-0.16
-0.13
-0.15
-0.12
-0.13
-0.13
Tangible Book Value per Share
- -
- -
- -
- -
- -
1
1
1
5
5
5
7
10
10
10
10
10
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
-12,143.64
-1,487.41
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-9
-4
-6
- -
- -
-1
-10
-5
-3
-1
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
-11,918.13
-1,590.92
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
5
6
1
- -
- -
- -
- -
4
- -
-1
-1
-1
-1
-2
-1
-1
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
5
6
6
- -
- -
- -
- -
4
1
-1
-1
-1
-1
-2
-1
-1
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
-10.06
- -
3.03
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
10
10
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Jun'25
Sep'25
Dec'25
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
1
1
Payables & Accruals
1
1
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-117.09%
0.76%
11%
Free Cash Flow
72.71%
-9.66%
-36.03%
Net Income, GAAP
152.43%
-85.46%
-132.2%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.01
-0.01
- -
- -
-0.02
2024
- -
-0.01
- -
- -
0.03
2025
-0.01
- -
- -
- -
-0.01

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
Apogee Therapeutics, Inc. (APGE)
Oncoinvent ASA (0RU5.L)
Zogenix, Inc. (ZGNX)
Werewolf Therapeutics, Inc. (HOWL)
InnoCare Pharma Limited (INCPF)
Agios Pharmaceuticals, Inc. (0HB0.L)
Business
NanoSphere Health Sciences Inc. is a nano-biotechnology company that develops and commercializes the patented NanoSphere Delivery System, a nanotechnology platform enhancing bioavailability, stability, solubility, and absorption of biologically active compounds including cannabinoids, supplements, nutraceuticals, pharmaceuticals, over-the-counter medications, cosmetics, and animal health products; the platform supports applications in pain management, anti-inflammatory treatments, neurological health, and cannabis delivery via transdermal, intranasal, and intraoral methods such as NanoSerum and Evolve Formulas brands. NanoSphere markets its technologies through licensing, joint ventures, and direct commercialization, primarily in the United States and Canada, with operations via wholly owned subsidiary NanoSphere Health Sciences LLC; founded in 2005 and headquartered in Vancouver, British Columbia, the company targets the cannabis, pharmaceutical, nutraceutical, cosmeceutical, and animal health industries. In recent developments, NanoSphere reported earnings results for the second quarter and six months ended June 30, 2025, reflecting ongoing financing activities including net cash from financing of $16,822 for the period, alongside continued focus on nano-delivery commercialization amid a low-revenue profile characteristic of its development-stage operations.